Clinical Trial Detail

NCT ID NCT02508870
Title A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

myelodysplastic syndrome

Therapies

Azacitidine

Atezolizumab

Age Groups: adult

No variant requirements are available.